MCLA-145
1 product
1 abstract
Abstract
Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab.Org: Gent University Hospital,
Product
MCLA-1451 product
1 abstract